Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - clindamycin phosphate, quantity: 1.188 % w/w - gel - excipient ingredients: propylene glycol; sodium hydroxide; purified water; hyetellose; ethanol; zinc acetate - zindaclin is indicated for the treatment of acne vulgaris, particularly forms in which comedones, papules and pustules predominate.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: polysorbate 20; triethyl citrate; mannitol; diacetylated monoglycerides; purified water; sodium benzoate; polysorbate 80; titanium dioxide; sucrose; propylene glycol; sorbic acid; maize starch; octoxinol; dimeticone 350; propyl hydroxybenzoate; purified talc; stearoyl macrogolglycerides; gelatin; hypromellose; methyl hydroxybenzoate; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pharmacy choice esomeprazole heartburn relief is indicated for the symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: lactose; crospovidone; glycerol dibehenate; hydrogenated castor oil; microcrystalline cellulose; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; hydrogenated castor oil; microcrystalline cellulose; maize starch; magnesium stearate; lactose monohydrate; croscarmellose sodium; povidone - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; povidone; microcrystalline cellulose; magnesium stearate; hydrogenated castor oil; maize starch; lactose monohydrate - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; povidone; hydrogenated castor oil; maize starch; magnesium stearate; lactose monohydrate; croscarmellose sodium - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; hyprolose; magnesium stearate; powdered cellulose; carmellose sodium; sodium sulfate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.